Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Implant Sciences/CardioTech

This article was originally published in The Gray Sheet

Executive Summary

Phase I Small Business Innovation Research Grant of $100,000 from NIH awarded to conduct research targeting improvements in drug delivery to abdominal aortic aneurysm (AAA) sites by incorporating heparin and rapamycin drugs into non-erodable, biodurable polyurethane graft coatings. Implant Sciences will provide a self-expanding, gold-coated Nitinol stent for improved radiopaque visualization, while CardioTech will contribute its ChronoFlex biodurable polyurethane loaded with rapamycin and coated with heparin. After a six-month trial is complete, an additional $750,000 Phase II grant may be available to develop the device into a commercial product...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel